This website is now the new JPND's archival platform. This website hosts all of JPND's archived content and resources.
Please continue to visit this site to access publications, videos and reports from JPND's activities.

Dev

Joined: October 9, 2025
Articles: 6278

survey

A multi-centre randomised controlled trial to compare the clinical and cost effectiveness of Lee Silverman Voice Treatment versus standard NHS speech and language therapy versus control in Parkinson’s disease (PD COMM)

A multi-centre randomised controlled trial to compare the clinical and cost effectiveness of Lee Silverman Voice Treatment versus standard NHS speech and language therapy versus control in Parkinson’s disease (PD COMM) Investments > €500k United Kingdom Parkinson’s disease & PD-related…

Dev
April 17, 2018

survey

Goal-oriented cognitive rehabilitation in early-stage Alzheimer’s disease: multi-centre single-blind randomised controlled trial (GREAT)

Goal-oriented cognitive rehabilitation in early-stage Alzheimer’s disease: multi-centre single-blind randomised controlled trial (GREAT) Investments > €500k United Kingdom Alzheimer’s disease & other dementias 2016

Dev
April 17, 2018

survey

A multi-centre randomised controlled trial of Comprehensive Geriatric Assessment in an admission avoidance hospital at home setting

A multi-centre randomised controlled trial of Comprehensive Geriatric Assessment in an admission avoidance hospital at home setting Investments > €500k United Kingdom Alzheimer’s disease & other dementias 2016

Dev
April 17, 2018

survey

Evaluating the effectiveness and cost effectiveness of Dementia Care Mapping (DCM) to enable person-centred Care for people with dementia and their carers: A UK cluster randomised controlled trial in care homes (DCM EPIC trial)

Evaluating the effectiveness and cost effectiveness of Dementia Care Mapping (DCM) to enable person-centred Care for people with dementia and their carers: A UK cluster randomised controlled trial in care homes (DCM EPIC trial) Investments > €500k United Kingdom Alzheimer’s…

Dev
April 17, 2018

survey

A large randomised assessment of the relative cost-effectiveness of different classes of drugs for Parkinson’s disease (PD MED)

A large randomised assessment of the relative cost-effectiveness of different classes of drugs for Parkinson’s disease (PD MED) Investments > €500k United Kingdom Parkinson’s disease & PD-related disorders 2016

Dev
April 17, 2018

survey

Mechanisms of neurotoxicity of amyloid aggregates.

Mechanisms of neurotoxicity of amyloid aggregates. Investments > €500k United Kingdom Alzheimer’s disease & other dementias 2016

Dev
April 17, 2018

survey

Consortium of Neuroimmunology of Mood Disorders and Alzheimer’s Disease.

Consortium of Neuroimmunology of Mood Disorders and Alzheimer’s Disease. Investments > €500k United Kingdom Alzheimer’s disease & other dementias 2016

Dev
April 17, 2018

survey

Molecular Basis of Protein Misfolding Disorders.

Molecular Basis of Protein Misfolding Disorders. Investments > €500k United Kingdom Neurodegenerative disease in general 2016

Dev
April 17, 2018

survey

Administration of VEGF (sNN0029) using an implanted drug delivery system for adose escalation study in patients with Amyotrophic Lateral Sclerosis.

Administration of VEGF (sNN0029) using an implanted drug delivery system for adose escalation study in patients with Amyotrophic Lateral Sclerosis. Investments > €500k United Kingdom Motor neurone diseases 2016

Dev
April 17, 2018

survey

Design and Optimisation of New Chemical Entities that Prevent the Neurotoxic Oligomerization and Misfolding of both beta-amyloid and tau Proteins: A Disease Modifying Therapeutics Approach for Alzheimer’s Dementia

Design and Optimisation of New Chemical Entities that Prevent the Neurotoxic Oligomerization and Misfolding of both beta-amyloid and tau Proteins: A Disease Modifying Therapeutics Approach for Alzheimer’s Dementia Investments > €500k United Kingdom Alzheimer’s disease & other dementias 2016 …

Dev
April 17, 2018

Post

Post